RT Journal Article
SR Electronic
T1 COVID-19 in Brazilian children and adolescents: findings from 21 hospitals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.08.21261510
DO 10.1101/2021.08.08.21261510
A1 Priscila Menezes Ferri Liu
A1 Maria do Carmo Barros de Melo
A1 Lilian Martins Oliveira Diniz
A1 Cristiane dos Santos Dias
A1 André Soares de Moura Costa
A1 Bárbara Lopes Farace
A1 Carla Thais Candida Alves da Silva
A1 Fernando Anschau
A1 Fernando Graça Aranha
A1 Guilherme Fagundes Nascimento
A1 Helena Duani
A1 Jamille Hemétrio Salles Martins Costa
A1 Karen Brasil Ruschel
A1 Matheus Carvalho Alves Nogueira
A1 Neimy Ramos de Oliveira
A1 Roberta Pozza
A1 Saionara Cristina Francisco
A1 Thalita Martins Lage
A1 Yuri Carlotto Ramires
A1 Daniella Nunes Pereira
A1 Zilma Silveira Nogueira Reis
A1 José Miguel Chatkin
A1 Milena Soriano Marcolino
YR 2021
UL http://medrxiv.org/content/early/2021/08/09/2021.08.08.21261510.abstract
AB Introduction Children and adolescents with Covid-19 have been shown lower mortality less intense symptoms when compared to adults, but studies in Brazil have been based on the compulsory notifying system only.Objective To analyse clinical, laboratory, radiological characteristics and outcomes of hospitalized patients under 20 years with Covid-19.Methods Cases series of hospitalized patients with confirmed Covid-19 under 20 years, obtained from a cohort study in 37 hospitals from five states of Brazil.Results From 36 patients, 20 (55.5%) were adolescentes, 20 (55.5%) were male, 18 (50.0%) had comorbidities, 2 were pregnant and in 7 (19.4%), initial symptoms occurred during hospitalization for other causes, of whom 3 were possibly infected in the hospital. Fever (61.1%), dyspnea (33.3%) and neurological symptoms (33.0%) were the most common complaints. C-reactive protein was higher than 50mg/L in 16.7% and D-dimer was above the reference limit in 22.2%. Chest X-rays were performed in 20 (55.5%) patients, 9 had abnormalities, and chest tomography in 5. Hospital length of stay ranged from 1-40 days (median 5 [interquartile range 3-10]), 16 (44.4%) needed intensive therapy, 6 (16.7%) required mechanical ventilation and one patient (2.8%) died.Conclusion In case series patients under 20 years from hospitals from 5 states of Brazil, comorbidities were frequent, and most common symptoms were fever, dyspnea and neurological symptoms. Forty-four percent required intensive therapy, showing that the disease was not as mild as it was expected, and one patient died.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received funding from Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) [grant number APQ-00208-20], Instituto de Avaliacao de Tecnologia em Saude (IATS), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [grant number n 465518 / 2014-1], Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [grant number 88887.507149 / 2020-00] and Pro-Reitoria de Extensao da UFMG (PROEX). Funders role Funders had no role in the study 's design; data collection, management, analysis and interpretation; manuscript writing; and decision of submission for publication. MSM and MCBM had access to the entire data of the study and were responsible for the decision to submit the paper. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the National Commission on Research Ethics (CAAE 30350820.5.1001.0008). Individual consent was dismissed due to the severity of the situation and because of the use of unidentified data, based only on the revision of medical records.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available through reasonable solicitation. Access, responsibility and data analysis The main authors (MSM and MCBM) had access to the entire study 's data and took on responsibility for data integrity and precision in data analysis.